Skip to main content
SpringerLink
Log in

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced number of cores are sufficient for histopathological diagnosis.

Methods

The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients with PSA > 75 ng/dl underwent bone scans first. Those with positive bone scans underwent a 2-core biopsy. Cancer detection rate and complications were analyzed to validate the findings of the first phase.

Results

In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with metastasis could be detected with a single core and 97.8% with a 2-core biopsy. In the prospective analysis, 52 patients with PSA > 75 were enrolled. 3/52 (5.7%) patients had a negative bone scan. 49 were assigned for 2-core biopsy, out of which 48 (97.9%) had a positive result. One patient underwent a repeat 12-core biopsy. The prospective cohort’s complications (p = 0.003) and pain score (p = 0.03) were lower compared to patients who underwent standard 12-core biopsies during phase one of the study period.

Conclusion

A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biopsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

All the patient related data available with the authors.

References

  1. Hebert JR, Ghumare SS, Gupta PC (2019) Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev 7(4):547–555

    Google Scholar 

  2. Hodge K, Mcneal J, Stamey T (1989) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142(1):66–70

    Article  CAS  PubMed  Google Scholar 

  3. Tanaka N, Shimada K, Nakagawa Y et al (2015) The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara urological research and treatment group nomogram. BMC Res Notes 8:689. https://doi.org/10.1186/s13104-015-1668-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mottet N, Cornford P, Van Den Bergh R, Briers V, De Santis M, Grummet J. et al. (2021) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines On Prostate Cancer. EAU Guidelines Office. Arnhem, The Netherlands: 2021. pp. 25–42. Available From: https://uroweb.org/wp-content/uploads/eau-eanm-estro-esur-isup-siog-guidelines-on-prostate-cancer-2021v4.pdf. [Accessed On 2021 Aug 7]

  5. Hodge K, Mcneal J, Terris M, Stamey T (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142(1):71–74

    Article  CAS  PubMed  Google Scholar 

  6. Naughton C, Miller D, Yan Y (2001) Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores. J Urol 165(1):100–103

    Article  CAS  PubMed  Google Scholar 

  7. Fuganti PE, Tobias-Machado M, Pinto MA, Simardi LH, Wroclawski ER. Twelve Core Prostate Biopsy Versus Six Systematic Sextant Biopsies. Accessed July 7, 2019. http://www.brazjurol.com.br/may_june_2002/Fuganti_ing_207_213.pdf

  8. Jiang J, Colli J, El-Galley R (2010) A simple method for estimating the optimum number of prostate biopsy cores needed to maintain high cancer detection rates while minimizing unnecessary biopsy sampling. J Endourol 24(1):143–147. https://doi.org/10.1089/end.2009.0285

    Article  PubMed  Google Scholar 

  9. Yücel C, Budak S, Kısa E, Celik O, Kozacıoglu Z (2018) The sufficiency of 6 core sextant prostate biopsy in patients with prostate specific antigen (PSA) values over 20 ng/mL. Arch Ital di Urol e Androl 90(2):104. https://doi.org/10.4081/aiua.2018.2.104

    Article  CAS  Google Scholar 

  10. Heyns CF, Naudé AM, Ahmed G, Stopforth HB, Stellmacher GA, Visser AJ (2001) Serum prostate-specific antigen as surrogate for the histological diagnosis of prostate cancer. S Afr Med J 91(8):685–689

    CAS  PubMed  Google Scholar 

  11. Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI (2002) The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol 168(5):1990–1993. https://doi.org/10.1097/01.ju.0000033330.06269.6d

    Article  CAS  PubMed  Google Scholar 

  12. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH (2002) Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60(5):826–830

    Article  PubMed  Google Scholar 

  13. Naughton CK, Ornstein DK, Smith DS, Catalona WJ (2000) Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 163(1):168–171

    Article  CAS  PubMed  Google Scholar 

  14. Han KS, Lee KH (2008) Korean urologic oncology society prostate cancer study group factors influencing pain during transrectal ultrasonography-guided prostate biopsy. Prostate Cancer Prostatic Dis 11(2):139–142. https://doi.org/10.1038/sj.pcan.4501004

    Article  CAS  PubMed  Google Scholar 

  15. Grummet J, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon D et al (2014) Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 114:384–388

    PubMed  Google Scholar 

  16. Laddha A, Thomas A, Nair DC, Ravindran GC, Pooleri GK (2020) Outcome of TRUS biopsy with limited cores in patients with PSA more than 50 ng/dL: can we reduce the number of cores without affecting outcomes? Indian J Surg Oncol 11(3):509–512. https://doi.org/10.1007/s13193-020-01165-9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    Sanjoy Kumar Sureka, Ankit Misra, Himanshu Raj, Anupam Shukla & Uday Pratap Singh

Authors
  1. Sanjoy Kumar Sureka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ankit Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Himanshu Raj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anupam Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uday Pratap Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjoy Kumar Sureka.

Ethics declarations

Informed consent

Written informed consent was obtained from all the participating patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sureka, S.K., Misra, A., Raj, H. et al. Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation. Int Urol Nephrol 55, 1133–1137 (2023). https://doi.org/10.1007/s11255-023-03531-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-023-03531-2

Keywords

Search

Navigation